- 全部删除
- 您的购物车当前为空
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 是一种抗体-药物偶联物 (ADC),由人源性抗SLC34A2抗体Lifastuzumab与连接子SMCC和细胞毒微管抑制剂DM1缀合而成。该ADC的毒性分子和连接子部分为SMCC-DM1。Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 可用于癌症研究。
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 是一种抗体-药物偶联物 (ADC),由人源性抗SLC34A2抗体Lifastuzumab与连接子SMCC和细胞毒微管抑制剂DM1缀合而成。该ADC的毒性分子和连接子部分为SMCC-DM1。Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 可用于癌症研究。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 12,000 | 待询 | |
5 mg | 待询 | 待询 |
产品描述 | Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked with the SMCC linker and the cytotoxic microtubule inhibitor DM1. The ADC's toxic and linker components are SMCC-DM1. Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 can be used for cancer research. |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容